Navigation Links
Genetic Immunity Presents Clinical Data on DermaVir Patch Immune Therapy at 15th Annual Conference on Retroviruses and Opportunistic Infections
Date:2/11/2008

Data Shows Excellent Safety Profile and Long Lasting Immunity

MCLEAN, Va., and BUDAPEST, Hungary, Feb. 11 /PRNewswire/ -- Genetic Immunity, a US/Hungarian clinical-stage biopharmaceutical company focusing on the development of its patented immunotherapeutic platform technology, announced clinical safety and immunogenicity data on its DermaVir Patch, a topically administered HIV immune therapy. The presentation, titled, "Single DermaVir Patch Treatment of HIV+ Individuals Induces Long Lasting, High Magnitude and Broad HIV-Specific T Cell Responses," was given at the 15th Annual Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, February 3-6, 2008.

Presently available antiretroviral drugs interfere with the viral life cycle, but because of their toxicity and resistance profiles are typically prescribed as late as possible in the disease progression. Recent findings with DermaVir Patch treatment suggest that this innovative medicine induces new HIV specific immune responses in HIV infected patients not achievable by antiretroviral drugs. Such an alternative treatment approach has the capability to address the needs of those HIV positive individuals who have not yet begun drug therapy as well as those who are currently on drug therapy.

Genetic Immunity studied nine HIV infected individuals on fully suppressive antiretroviral therapy who were treated a single time with either 0.1, 0.4 or 0.8 mg of multiple HIV antigens encoding plasmid DNA, the active substance in DermaVir Patch. The same antiretroviral drug regimen was continued during the one-year follow-up.

HIV-specific T cell Precursors with High Proliferative Capacity (PHPC) were quantified via an assay performed by Franco Lori, M.D. and his collaborators. The DermaVir Patch treatment resulted in significant induction of PHPC counts in all nine patients in the study. Importantly, these precursor T cell responses were long lasting, 10-100 fold increased PHPC counts over baseline were detected during the one year follow up. An independent study has demonstrated that PHPC count inversely correlates with viral load.

Safety was assessed with standard clinical and laboratory evaluations, and dermatological analysis of skin reaction. DermaVir Patch continued to show a lack of dose limiting toxicities. Through multiple studies, the only side effect seen so far has been limited to transient erythema (redness of the skin).

Julianna Lisziewicz, Ph.D., Co-Founder and CEO of Genetic Immunity, said, "The distinctive safety and immunogenicity data is consistent with our primate studies showing viral load reduction associated with immune responses induced by DermaVir Patch treatment. The Genetic Immunity team is encouraged by this data, which suggests that the DermaVir Patch is on its way to becoming the first immune therapy for HIV-infected individuals."

Franco Lori, M.D., CEO of Virostatics said, "In an independent experiment, we demonstrated that high PHPC counts significantly correlate with low viral load. The clinical results of the DermaVir Patch suggest a novel immunogenicity profile. We are hopeful that many patients may see benefit from this truly innovative antiviral therapy."

About Genetic Immunity(R)

Genetic Immunity is a US/Hungarian development stage company establishing leadership in next-generation biopharmaceuticals. The Company is leveraging its proprietary platform technology to create new markets for infectious diseases, cancer and allergy through the discovery, development and commercialization of topically administered immune therapies. These indications represent significant unmet medical need and potential for alternative treatment approaches. Genetic Immunity's lead product, the DermaVir Patch for the treatment of HIV/AIDS, was discovered by the Company's founders, and is in Phase II clinical development with the opportunity to be the first immune therapy approved for HIV-infected individuals.

About DermaVir Patch

The proprietary DermaVir Patch is a topically administered HIV immune therapy, which emerged from the clinical observations of Genetic Immunity's founders. Their examination of the "Berlin Patient" proved that induction of immune control of HIV replication is feasible in an infected patient. The Company has developed the DermaVir Patch to induce the immune system to kill HIV infected cells specifically and to make immune therapy accessible for the majority of HIV infected individuals, including children. The DermaVir Patch, currently in Phase II clinical trials, is comprised of two patented components: NanoComp and DermaPrep. NanoComp is an antigen composition platform that combines a disease-specific plasmid DNA with the Company's formulation technology. The unique DNA for the DermaVir Patch product encodes the majority of HIV antigens, allowing a broad immune response. DermaPrep is a topical administration device by which NanoComp is delivered specifically into the dendritic cells.

Contacts:

The Ruth Group

Investors

Sara Ephraim

+1-646-536-7002

sephraim@theruthgroup.com

Media

Janine McCargo

+1-646-536-7033

jmccargo@theruthgroup.com


'/>"/>
SOURCE Genetic Immunity
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
2. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
3. American Fertility Association Calls for Expanded Research to Advance New Technology to Screen Embryos for Genetic Abnormalities
4. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
5. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
6. 454 Sequencing(TM) in Science Today: Researchers Uncover a Genetic Basis for Different Social Behaviors in Wasps
7. Genetic Differences Predict Anti-Inflammatory Benefits From Nutritional Products
8. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
9. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
10. Genetics Determine Optimal Drug Dose of Common Anticoagulant
11. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016  Aralez Pharmaceuticals Inc. ("Aralez") today announced the ... Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval of the ... The combined company will operate under Aralez Pharmaceuticals Inc. ... Canada , Ireland ... Under the terms of the Agreement and Plan of ...
(Date:2/5/2016)... New York , February 5, 2016 ... new Transparency Market Research report states that the global ... in 2014 and is predicted to reach US$185.9 bn ... CAGR of 6.50% from 2014 to 2020. The title ... (Branded/Generic/Over-the-counter, Chemical/Biological, Captive/Contract Manufactured, by Geography, and by Therapeutic ...
(Date:2/5/2016)... -- Henry Schein, Inc. (NASDAQ: HSIC ), the world,s largest ... dental, animal health and medical practitioners, announced today that ... majority ownership interest in Dental Cremer S.A., a distributor ... . --> ... dental distribution business of Cremer S.A. With 2015 sales ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... February 06, 2016 , ... With the FCPX LUT: Summer ... grades to their footage. A LUT is a Lookup Table that contains a mathematical ... color indicated by the table. By manipulating each pixel, LUT's can change each color ...
(Date:2/5/2016)... ... 05, 2016 , ... VeloReality President and co-founder ... LYNX VR Indoor Trainer with multi-rider capability to an enthusiastic audience at the ... reduce the weight of the unit, they also enhance the rider's experience with ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
(Date:2/5/2016)... ... February 05, 2016 , ... US Sports Camps , official operators ... to direct high-performance kids yoga training. ChildLight Yoga Studio is centrally situated in the ... Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, “We are thrilled ...
(Date:2/5/2016)... ... February 05, 2016 , ... Boar’s Head Brand®, one of the nation’s ... weekend’s Big Game. Take the stress out of your party preparation – follow these ... at every stage of the game. , “The key to hosting a successful game-day ...
Breaking Medicine News(10 mins):